Home | Welcome to Contract Pharma   
Last Updated Friday, July 25 2014
Print RSS Feed

Search Results for 'Financial Reports: Biogen Idec'

Search For:
Refine by Dates:
From: To:
Past 7 Days        Past 30 Days
Refine By Content:

Search Results:

Published July 23, 2014
MS drug TECFIDERA drives growth in the quarter Read More »
Published April 23, 2014
51% growth driven by MS franchise Read More »
Published April 10, 2014
Koppel to lead corporate strategy and portfolio management Read More »
By Kristin Brooks
Published January 29, 2014
Expanded MS franchise drives growth Read More »
Published July 25, 2013
Revenues up 21% in the quarter with Tecfidera launch Read More »
By Gil Roth
Published January 28, 2013
MS franchise continues growth trend Read More »
Published October 25, 2012
Revenues up 6% in the quarter on Avonex boost Read More »
Published October 31, 2011
Revenues up 11% Read More »
Published April 21, 2011
Growth in the quarter was primarily driven by Tysabri revenues, up 15% to $251 million, and Avonex sales, up 8% to $642 million. Read More »
Published May 2, 2007
Biogen Idec 1Q Revenues: $716 million, (+17%) 1Q Earnings: $132 million (+7%) Comments: Growth in the quarter was driven by Avonex sales, up 14% to $449 million, and Rituxan revenues from the joint business arrangement with Genentech, up… Read More »
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On